Rxsight Inc (RXST) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Rxsight Inc stock (RXST) is currently trading at $6.26. Rxsight Inc PS ratio (Price-to-Sales) is 1.96. Analyst consensus price target for RXST is $10.06. WallStSmart rates RXST as Sell.
- RXST PE ratio analysis and historical PE chart
- RXST PS ratio (Price-to-Sales) history and trend
- RXST intrinsic value — DCF, Graham Number, EPV models
- RXST stock price prediction 2025 2026 2027 2028 2029 2030
- RXST fair value vs current price
- RXST insider transactions and insider buying
- Is RXST undervalued or overvalued?
- Rxsight Inc financial analysis — revenue, earnings, cash flow
- RXST Piotroski F-Score and Altman Z-Score
- RXST analyst price target and Smart Rating
Rxsight Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Rxsight Inc (RXST) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Rxsight Inc (RXST) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
90.06% of shares held by major funds and institutions
Paying $1.96 for every $1 of annual revenue
Supporting Valuation Data
Rxsight Inc (RXST) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -18.90%, a shrinking business
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Rxsight Inc (RXST) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 0.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.96), Price/Book (0.96) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -18.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -14.00%, Operating Margin at -34.80%, Profit Margin at -29.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -14.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -18.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RXST Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RXST's Price-to-Sales ratio of 1.96x trades at a deep discount to its historical average of 17.04x (0th percentile). The current valuation is 96% below its historical high of 43.95x set in Aug 2021, and 0% above its historical low of 1.96x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~7.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Rxsight Inc (RXST) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Rxsight Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 134M with 19% decline year-over-year. The company is currently unprofitable, posting a -29.0% profit margin.
Key Findings
Revenue contracted 19% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -29.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Rxsight Inc.
Bottom Line
Rxsight Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Rxsight Inc(RXST)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Rxsight Inc. is a pioneering healthcare technology company specializing in advanced vision correction solutions through its innovative diagnostic and surgical techniques in refractive eye surgery. Utilizing proprietary software and precision-guided laser technology, the company significantly improves patient outcomes and overall quality of life. Rxsight's strong intellectual property portfolio and strategic partnerships further enhance its competitive positioning within the expanding ophthalmic market. With a robust commitment to innovation and excellence, Rxsight is strategically poised for significant growth and impact in the evolving landscape of eye care.